What is Boehringer Ingelheim Hyvisc?

Boehringer Ingelheim Hyvisc is a sterile injection of hyaluronate sodium that is used for intra-articular injections in horses. It is manufactured and distributed by Boehringer Ingelheim Vetmedica , Inc., a leading animal health company with a focus on producing innovative and high-quality products for animals. Hyvisc is designed to help manage the symptoms of joint disease in horses, such as osteoarthritis, and is often used in conjunction with other therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs).

The active ingredient in Hyvisc is a naturally occurring substance found in the body called hyaluronic acid. Hyaluronic acid is a key component of synovial fluid in joints and is responsible for lubrication and shock absorption. In horses with joint disease, the amount and quality of hyaluronic acid in the synovial fluid can be reduced, leading to pain, inflammation, and joint degeneration. Hyvisc works by supplementing the hyaluronic acid in the joint fluid, helping to restore its normal function and providing relief from joint pain and inflammation.

Hyvisc has been extensively studied and clinically tested for safety and efficacy, and has been shown to be a safe and effective treatment option for managing joint disease in horses. It is available in a prefilled syringe for easy administration and is typically given by an experienced veterinarian.

Overall, Boehringer Ingelheim Hyvisc is an important therapy for managing joint disease in horses, helping to alleviate pain, reduce inflammation, and improve joint function. It is just one example of the many innovative and high-quality products produced by Boehringer Ingelheim Vetmedica, Inc. to support the health and well-being of animals.